Visionary Pharmaceuticals Overview

  • Founded
  • 2010
Founded
  • Status
  • Private
  • Latest Deal Type
  • Grant
  • Investors
  • 2

Visionary Pharmaceuticals General Information

Description

Developer of drugs for cancer treatment. The company operates a biotechnology company which develops drugs for medical needs for cancer and inflammation treatement.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 11555 Sorrento Valley Road
  • Suite A
  • San Diego, CA 92121
  • United States
+1 (858) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Visionary Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Grant 05-Mar-2013 Completed Startup
2. Accelerator/Incubator 17-Sep-2012 Completed Startup
1. Seed Round 27-Jul-2011 Completed Startup
To view Visionary Pharmaceuticals’s complete valuation and funding history, request access »

Visionary Pharmaceuticals Executive Team (3)

Name Title Board Seat Contact Info
Gordon Alton Ph.D Co-Founder, Chief Executive Officer, President & Director
Louis Tommasino Chief Financial Officer
Ayse Batova Ph.D Co-Founder, Vice President of Biology & Director
To view Visionary Pharmaceuticals’s complete executive team members history, request access »

Visionary Pharmaceuticals Board Members (1)

Name Representing Role Since
John Westwick Ph.D Self Board Member 000 0000
To view Visionary Pharmaceuticals’s complete board members history, request access »

Visionary Pharmaceuticals Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
The National Institute of Diabetes and Digestive and Kidney Diseases Government 000 0000 000000 0
CONNECT (Accelerator) Accelerator/Incubator Minority 000 0000 000000 0
To view Visionary Pharmaceuticals’s complete investors history, request access »